Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7345102 | 0.90 | CASP1 (0.33) | CASP1MAPT | |
| SCHEMBL1409128 | 0.90 | CASP1 (0.33) | CASP1MAPT | |
| SCHEMBL646188 | 0.69 | CASP1 (0.44) | CASP1 | |
| SCHEMBL646998 | 0.69 | CASP1 (0.53) | CASP1 | |
| SCHEMBL647269 | 0.68 | CASP1 (0.48) | CASP1MAPT | |
| SCHEMBL644763 | 0.68 | ADRB2 (0.44) | CASP1 | |
| SCHEMBL645196 | 0.66 | CASP1 (0.45) | CASP1 | |
| SCHEMBL5831798 | 0.61 | KLK5 (0.50) | CASP1 | |
| SCHEMBL9697852 | 0.61 | CASP1 (0.43) | CASP1 | |
| SCHEMBL26623307 | 0.60 | CASP1 (0.43) | CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CASP1 6/4885MAPT 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.